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Introduction
A new group of autoinflammatory diseases caused by
immunoproteasome dysfunction has been recently
reported. The mutation in the PSMB8 gene encoding
immunoproteasome subunit b type 8 causes a number of
clinical syndromes that described as chronic atypical neu-
trophilic dermatosis with lipodystrophy and elevated tem-
perature (CANDLE) syndrome and Nakajo-Nishimura
syndrome (NNS).
Case Report
A Japanese girl presented with fever, annular erythematous
plagues and elevation of hepatocellular enzyme at
2 months of age. She had deformed ears, a broad saddle-
like nose and periorbital edema. At 16 years of age, she
had lipodystrophy of the face and upper limbs, a protuber-
ant abdomen, and severe fat deposition into the peritoneal
and the pleural cavity. Painful nodular erythema, hepatos-
plenomegaly, muscle atrophy, mild joint contracture of
ankle, and mild mental retardation were observed. She
suffered from arthralgia without arthritis for her lifelong.
Laboratory findings showed hypochromic anemia, and ele-
vation of erythrocyte sedimentation rate and C-reactive
protein. A brain computed tomographic image revealed
basal ganglia calcification. After obtaining informed
consent, the patient’s DNA was analyzed for mutations in
PSMB8, and heterozygous c145C>A mutation (Q49K) was
found. She was unsuccessfully treated with NSAIDs, a
variety of immunosuppressants: cyclosporine, tacrolimus
and mycophenolate mofetil, and biologics: infliximab and
tocilizumab. Pulsed intravenous methylprednisolone and
high dose of oral prednisolone (PSL) were effective. Thali-
domide had an efficacy for improvement in her symptoms
and reduction of PSL dosage, but the treatment had to be
terminated due to thrombocytopenia.
Discussion
We reported here the case of severe CANDLE syndrome.
Although both her disease course and clinical presenta-
tions were typical, only heterozygous Q49K mutation in
the PSMB8 gene was found. Recent studies showed
that thalidomide combined with statin was involved in
anti-myeloma action by p38 MAPK inhibition, as well as
thalidomide inhibits lipopolysaccharide-induced tumor
necrosis factor a production. The efficacy of thalidomide
in our case indicates that thalidomide could regulate the
inflammatory signaling induced by immunoproteasome
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